GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2010

Tanabe Research Labs and Anaphore Ally to Develop Atrimers for Autoimmune Diseases

  • Tanabe Research Laboratories is teaming up with Anaphore for an R&D program that aims to develop protein therapeutics for autoimmune diseases based on the latter’s Atrimer™ technology. The aim is to generate trivalent Atrimer proteins targeting autoimmune disorders including rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

    Anaphore’s Atrimer technology is based on the human trivalent plasma protein tetranectin, which exhibits three binding domains. Each of these comprises five distinct amino-acid loops that can be programmed to bind potently and specifically to virtually any target of interest, Anaphore claims. Although the target will typically be a cell-surface receptor or ligand protein with a trimeric structure, the Atrimer technology also enables the design of candidates directed to nontrimeric targets including carbohydrates, the firm adds.

    Anaphore’s existing pipeline comprises preclinical Atrimer and aptamer-drug conjugate candidates in development for the potential treatment of inflammatory disease and cancer. Lead candidate ATX3105 is an IL-23 receptor antagonist in development for the treatment of inflammatory bowel disease, psoriasis, multiple sclerosis, and rheumatoid arthritis. Anaphore claims preclinical studies have shown ATX3105 demonstrates potent and selective inhibition of the downstream IL-23 pathway.

    Established in 1990, Tanabe Research Laboratories is a U.S. subsidiary of Japan’s Mitsubishi Tanabe Pharma. The firm was initially focused on small molecule drug discovery in the field of metabolics and inflammation/immunology. However, a restructuring earlier in 2010 means it is now dedicated to the development of antibodies and biologics for the treatment of autoimmune diseases. In June Tanabe Research started operations at its new facility in San Diego.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?